<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00390832</url>
  </required_header>
  <id_info>
    <org_study_id>GE IDE No. I01106</org_study_id>
    <nct_id>NCT00390832</nct_id>
  </id_info>
  <brief_title>Efficacy Study of Erythropoietin After Revascularization in Myocardial Infarction (REVIVAL-3)</brief_title>
  <acronym>REVIVAL-3</acronym>
  <official_title>Prospective, Randomized, Double-Blind, Placebo-Controlled Trial of Erythropoietin in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention (REVIVAL-3)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deutsches Herzzentrum Muenchen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deutsches Herzzentrum Muenchen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether erythropoietin is superior to placebo with
      respect to left ventricular ejection fraction in patients with ST-elevation myocardial
      infarction undergoing percutaneous coronary intervention.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Erythropoietin has lately been shown to exert others than merely hematopoietic functions. Due
      to attenuation of cell apoptosis and necrosis and/or enhancing neovascularisation,
      erythropoietin could be protective after myocardial ischemia and reperfusion and lead to
      infarct size reduction and improvement in left ventricular function. In a controlled clinical
      trial, short-term administration of erythropoietin in patients with ischemic stroke was
      associated with a significantly better functional recovery, with a lower level of circulating
      damage markers and a strong trend to smaller infarct sizes measured by magnetic resonance
      imaging. While leaving hematocrit and platelet counts unchanged, short-term administration of
      erythropoietin was shown to be safe and very well tolerated (no side effects reported or
      observed). The protective effects of short-term erythropoietin in acute ischemic brain damage
      are further evaluated in an ongoing multi-center trial in Germany. Considering the
      preclinical and clinical data erythropoietin is an attractive candidate to be evaluated in
      patients with acute myocardial infarction. In a pilot trial enrolling 22 patients with acute
      myocardial infarction short-term administration of erythropoietin was shown to be safe and to
      significantly increase the level of endothelial progenitor cells after percutaneous coronary
      intervention. However, the very small population did not allow evaluating the benefit in left
      ventricular function or clinical outcomes.

      The aim of the REVIVAL-3 study is to investigate whether there is additional benefit of
      short-term administration of erythropoietin in patients with acute myocardial infarction
      after successful primary percutaneous coronary intervention (PCI) in terms of left
      ventricular ejection fraction.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Left ventricular ejection fraction measured by magnetic resonance imaging</measure>
    <time_frame>4-6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in left ventricular ejection fraction and infarct size</measure>
    <time_frame>over 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death, recurrent myocardial infarction, IRA-revascularization and stroke</measure>
    <time_frame>30 days, 6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">138</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Angioplasty, Transluminal, Percutaneous Coronary</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>recombinant human erythropoietin beta</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% NaCl solution</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erythropoietin</intervention_name>
    <description>33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU</description>
    <arm_group_label>A</arm_group_label>
    <other_name>NeoRecormon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.</description>
    <arm_group_label>B</arm_group_label>
    <other_name>0.9% NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with ST-Segment elevation myocardial infarction &lt;24 h from pain onset

          -  Successful primary PCI and left ventricular ejection fraction &lt;50%

          -  Informed, written consent

          -  In women with childbearing potential a pregnancy test is mandatory

        Exclusion Criteria:

          -  Age &lt; 18 and &gt; 80 years

          -  Cardiogenic shock

          -  pericarditis

          -  thrombolysis for the index infarction

          -  malignancies/other comorbid conditions with life expectancy &lt; 1 year

          -  previous myocardial infarction

          -  planned staged PCI or prior PCI within 30 days from index procedure

          -  uncontrolled hypertension &gt;160/100mmHg unresponsive to therapy

          -  epilepsy

          -  active bleeding; bleeding diathesis; history of gastrointestinal or genitourinary
             bleeding, recent trauma or major surgery &lt; 1 month; history of intracranial bleeding
             or structural abnormalities; suspected aortic dissection; patient's refusal to blood
             transfusion

          -  hematologic disorders such as essential thrombocytosis, megakaryoblastic leukemia,
             polycythemia vera

          -  relevant hematologic deviations: hemoglobin &lt; 100 g/l or hemoglobin &gt; 160 g/l platelet
             count &lt; 100 x 10^9 cells/l or platelet count &gt; 600 x 10^9 cells/l

          -  any contraindication to magnetic resonance imaging: electronically, magnetically and
             mechanically activated implants such as cardiac pacemakers, automatic cardioverter
             defibrillators, joint prostheses, surgical/vascular clips/ hearing aids,
             neurostimulators, infusion pumps etc metallic splinters in the eye ferromagnetic
             haemostatic clips in the central nervous system cochlear implants lead wires or
             similar wires prosthetic heart valves, if dehiscence is suspected non-ferromagnetic
             stapedial implants, hemostatic clips

          -  glomerular filtration rate &lt; 30 ml/min or serum creatinine &gt; 30 mg/l or dependence on
             renal dialysis

          -  chronic liver disease with GOT &gt; 5-fold over the normal range

          -  allergy to erythropoietin/true anaphylaxis after prior exposure to contrast media

          -  phenylketonuria

          -  previous enrollment in this trial

          -  women who are known to be pregnant, who are of childbearing potential and test
             positive for pregnancy, who have given birth within the last 90 days, who are
             breastfeeding

          -  patient's inability to fully cooperate with the study protocol

          -  other contraindication according to the summary of product characteristics of
             recombinant human erythropoietin beta (NeoRecormonÂ®)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Albert Schomig, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilka Ott, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Deutsches Herzzentrum Muenchen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Deutsches Herzzentrum Muenchen</name>
      <address>
        <city>Munich</city>
        <zip>80636</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>1. Medizinische Klinik, Klinikum rechts der Isar</name>
      <address>
        <city>Munich</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Kastrati A, Mehilli J, Dirschinger J, Schricke U, Neverve J, Pache J, Martinoff S, Neumann FJ, Nekolla S, Blasini R, Seyfarth M, Schwaiger M, SchÃ¶mig A; Stent versus Thrombolysis for Occluded Coronary Arteries in Patients With Acute Myocardial Infarction (STOPAMI-2) Study. Myocardial salvage after coronary stenting plus abciximab versus fibrinolysis plus abciximab in patients with acute myocardial infarction: a randomised trial. Lancet. 2002 Mar 16;359(9310):920-5.</citation>
    <PMID>11918909</PMID>
  </reference>
  <reference>
    <citation>ZohlnhÃ¶fer D, Hausleiter J, Kastrati A, Mehilli J, Goos C, SchÃ¼hlen H, Pache J, Pogatsa-Murray G, Heemann U, Dirschinger J, SchÃ¶mig A. A randomized, double-blind, placebo-controlled trial on restenosis prevention by the receptor tyrosine kinase inhibitor imatinib. J Am Coll Cardiol. 2005 Dec 6;46(11):1999-2003. Epub 2005 Nov 4.</citation>
    <PMID>16325031</PMID>
  </reference>
  <reference>
    <citation>Pache J, Kastrati A, Mehilli J, Bollwein H, Ndrepepa G, SchÃ¼hlen H, Martinoff S, Seyfarth M, Nekolla S, Dirschinger J, Schwaiger M, SchÃ¶mig A. A randomized evaluation of the effects of glucose-insulin-potassium infusion on myocardial salvage in patients with acute myocardial infarction treated with reperfusion therapy. Am Heart J. 2004 Jul;148(1):e3.</citation>
    <PMID>15215812</PMID>
  </reference>
  <reference>
    <citation>Sadamoto Y, Igase K, Sakanaka M, Sato K, Otsuka H, Sakaki S, Masuda S, Sasaki R. Erythropoietin prevents place navigation disability and cortical infarction in rats with permanent occlusion of the middle cerebral artery. Biochem Biophys Res Commun. 1998 Dec 9;253(1):26-32.</citation>
    <PMID>9875214</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Timner W, SirÃ©n AL. A novel role for an established player: anemia drug erythropoietin for the treatment of cerebral hypoxia/ischemia. Transfus Apher Sci. 2004 Aug;31(1):39-44. Review.</citation>
    <PMID>15294194</PMID>
  </reference>
  <reference>
    <citation>Ehrenreich H, Hasselblatt M, Dembowski C, Cepek L, Lewczuk P, Stiefel M, Rustenbeck HH, Breiter N, Jacob S, Knerlich F, Bohn M, Poser W, RÃ¼ther E, Kochen M, Gefeller O, Gleiter C, Wessel TC, De Ryck M, Itri L, Prange H, Cerami A, Brines M, SirÃ©n AL. Erythropoietin therapy for acute stroke is both safe and beneficial. Mol Med. 2002 Aug;8(8):495-505.</citation>
    <PMID>12435860</PMID>
  </reference>
  <results_reference>
    <citation>Ott I, Schulz S, Mehilli J, Fichtner S, Hadamitzky M, Hoppe K, Ibrahim T, Martinoff S, Massberg S, Laugwitz KL, Dirschinger J, Schwaiger M, Kastrati A, Schmig A; REVIVAL-3 Study Investigators. Erythropoietin in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a randomized, double-blind trial. Circ Cardiovasc Interv. 2010 Oct;3(5):408-13. doi: 10.1161/CIRCINTERVENTIONS.109.904425. Epub 2010 Aug 24.</citation>
    <PMID>20736448</PMID>
  </results_reference>
  <verification_date>March 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 19, 2006</study_first_submitted>
  <study_first_submitted_qc>October 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2006</study_first_posted>
  <last_update_submitted>December 16, 2010</last_update_submitted>
  <last_update_submitted_qc>December 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Prof. A. SchÃ¶mig</name_title>
    <organization>Deutsches Herzzentrum Munich</organization>
  </responsible_party>
  <keyword>STEMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

